296 related articles for article (PubMed ID: 21145860)
1. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.
Gehring AJ; Xue SA; Ho ZZ; Teoh D; Ruedl C; Chia A; Koh S; Lim SG; Maini MK; Stauss H; Bertoletti A
J Hepatol; 2011 Jul; 55(1):103-10. PubMed ID: 21145860
[TBL] [Abstract][Full Text] [Related]
2. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
3. Immune-Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B-Infected Cells.
Fergusson JR; Wallace Z; Connolly MM; Woon AP; Suckling RJ; Hine DW; Barber C; Bunjobpol W; Choi BS; Crespillo S; Dembek M; Dieckmann N; Donoso J; Godinho LF; Grant T; Howe D; McCully ML; Perot C; Sarkar A; Seifert FU; Singh PK; Stegmann KA; Turner B; Verma A; Walker A; Leonard S; Maini MK; Wiederhold K; Dorrell L; Simmons R; Knox A
Hepatology; 2020 Nov; 72(5):1528-1540. PubMed ID: 32770836
[TBL] [Abstract][Full Text] [Related]
4. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
[TBL] [Abstract][Full Text] [Related]
5. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.
Kah J; Koh S; Volz T; Ceccarello E; Allweiss L; Lütgehetmann M; Bertoletti A; Dandri M
J Clin Invest; 2017 Aug; 127(8):3177-3188. PubMed ID: 28737510
[TBL] [Abstract][Full Text] [Related]
6. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
7. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma.
Liu Q; Tian Y; Li Y; Zhang W; Cai W; Liu Y; Ren Y; Liang Z; Zhou P; Zhang Y; Bao Y; Li Y
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323464
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.
Shi M; Qian S; Chen WW; Zhang H; Zhang B; Tang ZR; Zhang Z; Wang FS
Clin Exp Immunol; 2007 Feb; 147(2):277-86. PubMed ID: 17223969
[TBL] [Abstract][Full Text] [Related]
9. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Yang F; Zheng X; Koh S; Lu J; Cheng J; Li P; Du C; Chen Y; Chen X; Yang L; Chen W; Wong RW; Wai LE; Wang T; Zhang Q; Chen W
Hepatol Int; 2023 Aug; 17(4):850-859. PubMed ID: 37067675
[TBL] [Abstract][Full Text] [Related]
10. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.
Otano I; Escors D; Schurich A; Singh H; Robertson F; Davidson BR; Fusai G; Vargas FA; Tan ZMD; Aw JYJ; Hansi N; Kennedy PTF; Xue SA; Stauss HJ; Bertoletti A; Pavesi A; Maini MK
Mol Ther; 2018 Nov; 26(11):2553-2566. PubMed ID: 30217730
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
[TBL] [Abstract][Full Text] [Related]
12. Small hepatitis B virus surface antigen promotes malignant progression of hepatocellular carcinoma via endoplasmic reticulum stress-induced FGF19/JAK2/STAT3 signaling.
Wu S; Ye S; Lin X; Chen Y; Zhang Y; Jing Z; Liu W; Chen W; Lin X; Lin X
Cancer Lett; 2021 Feb; 499():175-187. PubMed ID: 33249195
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
15. Mutation "hot spot" in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma.
Chen WN; Oon CJ
Biochem Biophys Res Commun; 1999 Sep; 262(3):757-61. PubMed ID: 10471398
[TBL] [Abstract][Full Text] [Related]
16. Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma.
Khlaiphuengsin A; Chuaypen N; Sodsai P; Buranapraditkun S; Boonpiyathad T; Hirankarn N; Tangkijvanich P
World J Gastroenterol; 2020 May; 26(20):2645-2656. PubMed ID: 32523317
[TBL] [Abstract][Full Text] [Related]
17. The Adaptive Immune Response in Hepatitis B Virus-Associated Hepatocellular Carcinoma Is Characterized by Dysfunctional and Exhausted HBV-Specific T Cells.
Broholm M; Mathiasen AS; Apol ÁD; Weis N
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793588
[TBL] [Abstract][Full Text] [Related]
18. Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.
Wisskirchen K; Metzger K; Schreiber S; Asen T; Weigand L; Dargel C; Witter K; Kieback E; Sprinzl MF; Uckert W; Schiemann M; Busch DH; Krackhardt AM; Protzer U
PLoS One; 2017; 12(8):e0182936. PubMed ID: 28792537
[TBL] [Abstract][Full Text] [Related]
19. HBV induced hepatocellular carcinoma and related potential immunotherapy.
Jia L; Gao Y; He Y; Hooper JD; Yang P
Pharmacol Res; 2020 Sep; 159():104992. PubMed ID: 32505833
[TBL] [Abstract][Full Text] [Related]
20. Adoptive T-cell therapy for HBV-associated HCC and HBV infection.
Tan AT; Schreiber S
Antiviral Res; 2020 Apr; 176():104748. PubMed ID: 32087191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
